EP1996937A4 - Genetic packages and uses thereof - Google Patents

Genetic packages and uses thereof

Info

Publication number
EP1996937A4
EP1996937A4 EP07752549A EP07752549A EP1996937A4 EP 1996937 A4 EP1996937 A4 EP 1996937A4 EP 07752549 A EP07752549 A EP 07752549A EP 07752549 A EP07752549 A EP 07752549A EP 1996937 A4 EP1996937 A4 EP 1996937A4
Authority
EP
European Patent Office
Prior art keywords
genetic packages
packages
genetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07752549A
Other languages
German (de)
French (fr)
Other versions
EP1996937A2 (en
Inventor
Volker Schellenberger
Willem P Stemmer
Chia-Wei Wang
Michael D Scholle
Mikhail Popkov
Nathaniel C Gordon
Andreas Crameri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amunix Pharmaceuticals Inc
Original Assignee
Amunix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38475542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1996937(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/528,927 external-priority patent/US20070191272A1/en
Application filed by Amunix Inc filed Critical Amunix Inc
Publication of EP1996937A2 publication Critical patent/EP1996937A2/en
Publication of EP1996937A4 publication Critical patent/EP1996937A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP07752549A 2006-03-06 2007-03-06 Genetic packages and uses thereof Withdrawn EP1996937A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74341006P 2006-03-06 2006-03-06
US74362206P 2006-03-21 2006-03-21
US11/528,927 US20070191272A1 (en) 2005-09-27 2006-09-27 Proteinaceous pharmaceuticals and uses thereof
US11/528,950 US20070212703A1 (en) 2005-09-27 2006-09-27 Proteinaceous pharmaceuticals and uses thereof
PCT/US2007/005857 WO2007103455A2 (en) 2006-03-06 2007-03-06 Genetic packages and uses thereof

Publications (2)

Publication Number Publication Date
EP1996937A2 EP1996937A2 (en) 2008-12-03
EP1996937A4 true EP1996937A4 (en) 2009-04-08

Family

ID=38475542

Family Applications (3)

Application Number Title Priority Date Filing Date
EP07752549A Withdrawn EP1996937A4 (en) 2006-03-06 2007-03-06 Genetic packages and uses thereof
EP07752636.6A Active EP1996220B2 (en) 2005-09-27 2007-03-06 Unstructured recombinant polymers and uses thereof
EP20140189047 Ceased EP2863222A1 (en) 2006-03-06 2007-03-06 Unstructured recombinant polymers and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP07752636.6A Active EP1996220B2 (en) 2005-09-27 2007-03-06 Unstructured recombinant polymers and uses thereof
EP20140189047 Ceased EP2863222A1 (en) 2006-03-06 2007-03-06 Unstructured recombinant polymers and uses thereof

Country Status (6)

Country Link
EP (3) EP1996937A4 (en)
AU (2) AU2007223855B2 (en)
CA (1) CA2644712C (en)
DK (1) DK2402754T4 (en)
SI (1) SI2402754T2 (en)
WO (2) WO2007103515A2 (en)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060403A2 (en) 2003-01-06 2004-07-22 Angiochem Inc. Aprotinin and anglos as carriers across the blood-brain barrier
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
AU2007223855B2 (en) 2006-03-06 2013-05-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
SI2173890T1 (en) 2007-06-21 2011-06-30 Univ Muenchen Tech Biological active proteins having increased in vivo and/or vitro stability
JP2010536341A (en) * 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド Compositions and methods for altering properties of biologically active polypeptides
CN102131516B (en) 2008-06-27 2016-03-16 杜克大学 Therapeutics comprising elastin-like peptides
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
ES2610356T3 (en) * 2009-02-03 2017-04-27 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising the same
AU2015218510B2 (en) * 2009-02-03 2016-11-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
AU2014206217B2 (en) * 2009-02-03 2015-09-17 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
MX2011011023A (en) 2009-04-20 2012-01-20 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog.
WO2010144508A1 (en) * 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
KR101813727B1 (en) * 2009-06-08 2018-01-02 아뮤닉스 오퍼레이팅 인코포레이티드 Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
RU2012103240A (en) * 2009-07-02 2013-08-10 Ангиокем Инк. MULTI-DIMENSIONAL PEPTIDE CONJUGATES AND THEIR APPLICATION
CA2771999A1 (en) * 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
EP2502939B1 (en) * 2009-11-19 2016-01-27 Zhejiang University Nonnatural collagen-like protein and use thereof
SI2506868T1 (en) 2009-12-06 2018-04-30 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
US8557961B2 (en) 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
ES2993140T3 (en) * 2010-04-02 2024-12-23 Amunix Pharmaceuticals Inc Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR081361A1 (en) 2010-04-30 2012-08-29 Molecular Partners Ag MODIFIED UNION PROTEINS THAT INHIBIT THE RECEPTOR INTERACTION OF THE VASCULAR ENDOTELIAL GROWTH FACTOR FROM GLICOPROTEIN TO VEGF-A
US9221882B2 (en) 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
ES2486321T3 (en) 2010-06-18 2014-08-18 Xiberscience Gmbh Peptides as active agents to stabilize biological barriers
PL3552619T3 (en) 2010-07-09 2025-12-01 Bioverativ Therapeutics Inc. Factor ix polypeptides and methods of use thereof
PL2643349T3 (en) 2010-11-26 2020-03-31 Molecular Partners Ag Designed repeat proteins binding to serum albumin
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
PT3513804T (en) 2011-07-08 2022-06-02 Bioverativ Therapeutics Inc Factor viii chimeric and hybrid polypeptides, and methods of use thereof
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
CN104271150A (en) * 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 Chimeric factor viii polypeptides and uses thereof
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
JP6256882B2 (en) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド Factor VIII composition, and method of making and use of the composition
JP6355563B2 (en) 2012-02-27 2018-07-11 アムニクス オペレーティング インコーポレイテッド XTEN conjugate composition and method for producing the same
ES2753135T3 (en) 2012-05-07 2020-04-07 Allergan Inc Treatment method of AMD in patients resistant to anti-VEGF therapy
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
CN104661674A (en) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 Factor VIII complexes with XTEN and von Willebrand Factor protein, and uses thereof
HK1213521A1 (en) 2012-09-25 2016-07-08 Bioverativ Therapeutics Inc. Methods of using fix polypeptides
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
TW202003554A (en) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 Factor VIII-XTEN fusions and uses thereof
PT3065761T (en) 2013-11-05 2020-02-21 Allergan Inc Method of treating conditions of the eye with an anti-vegf darpin
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
WO2015195531A2 (en) 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
KR102427117B1 (en) 2015-04-02 2022-07-29 몰리큘라 파트너스 아게 Designed ankyrin repeat domain with binding specificity for serum albumin
ES2784603T3 (en) 2015-06-02 2020-09-29 Novo Nordisk As Insulins with recombinant polar extensions
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
EA201890423A1 (en) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. SLIGHT PROTEINS OF THE FACTOR IX, METHODS OF THEIR RECEPTION AND APPLICATION
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide assembly and methods of making and using the same
EP3355931B1 (en) 2015-10-01 2024-06-26 Novo Nordisk A/S Protein conjugates
CN109689096A (en) 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 Variant PD-L1 polypeptides, T cell regulatory multimer polypeptides, and methods of using the same
WO2017201210A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
MX2019006444A (en) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc HEMOPHILIC ARTHROPATHY TREATMENT METHODS USING CHEMERIC COAGULATION FACTORS.
ES2973548T3 (en) 2016-12-22 2024-06-20 Cue Biopharma Inc Multimeric T cell modulating polypeptides and methods for their use
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
JP2020513019A (en) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス Oligomer-extended insulin-Fc conjugate
JP2020534352A (en) 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド T cell regulatory multimeric polypeptide with conjugation site and how to use it
CN111886241A (en) 2018-01-09 2020-11-03 库尔生物制药有限公司 Multimeric T cell modulating polypeptides and methods of use thereof
WO2019201855A1 (en) * 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Lysosomal fusion protein
PL3793588T3 (en) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
TWI856047B (en) 2018-12-19 2024-09-21 美商信號生物製藥公司 Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2022522405A (en) 2019-03-06 2022-04-19 キュー バイオファーマ， インコーポレイテッド T cell regulatory multimeric polypeptide and its usage
EP3935079A4 (en) 2019-03-06 2023-03-22 Cue Biopharma, Inc. T LYMPHOCYTE MODULATOR ANTIGEN PRESENTING POLYPEPTIDES AND METHODS OF USE THEREOF
CA3138805A1 (en) 2019-06-04 2020-12-10 Johannes Schilling Designed ankyrin repeat domain with improved stability
JP2023538533A (en) 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー FGF21 in combination with CCR2/5 antagonists for the treatment of fibrosis
CN114729060B (en) 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 Polypeptide conjugates and methods of use
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
WO2022123459A1 (en) 2020-12-11 2022-06-16 Friedrich Miescher Institute For Biomedical Research Hdac6 binding proteins and their anti-viral use
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
CN115083016A (en) * 2022-06-09 2022-09-20 广州紫为云科技有限公司 Monocular camera-based small-target-oriented hand space interaction method and device
KR20250075704A (en) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. Long-acting parathyroid hormone

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD257197A1 (en) † 1987-01-28 1988-06-08 Univ Dresden Tech METHOD FOR THE PRODUCTION OF IMMOBILIZED INSULIN PRAEPARATIONS STABILIZED IN ITS BIOLOGICAL ACTIVITY AND MODIFIED IN ITS PHARMACOLOGICAL PROPERTIES
FR2647677B1 (en) * 1989-05-31 1991-09-27 Roussel Uclaf NOVEL MICRO-PROTEINS, PROCESS FOR THE PREPARATION AND APPLICATION AS MEDICAMENTS OF SUCH NEW MICRO-PROTEINS
HUT69963A (en) † 1990-12-13 1995-09-28 Upjohn Co Non-naturally-occuring fusion proteins and process for preparing them
US5833911A (en) † 1995-05-31 1998-11-10 Johnson & Johnson Medical, Inc. Method for forming a glove using a folded glove form
AU5065198A (en) † 1996-11-15 1998-06-10 Maria Grazia Masucci Fusion proteins having increased half-lives
EP1054973A1 (en) * 1998-02-11 2000-11-29 Maxygen, Inc. Antigen library immunization
US20050260605A1 (en) * 1998-02-11 2005-11-24 Maxygen, Inc. Targeting of genetic vaccine vectors
US20050287153A1 (en) † 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20030049689A1 (en) * 2000-12-14 2003-03-13 Cynthia Edwards Multifunctional polypeptides
US20020169125A1 (en) * 2001-03-21 2002-11-14 Cell Therapeutics, Inc. Recombinant production of polyanionic polymers and uses thereof
BRPI0606934A2 (en) † 2005-01-25 2017-07-11 Cell Therapeutics Inc BIOLOGICALLY ACTIVE PROTEIN CONJUGATE, COMPOSITION, CHIMERIC DNA MOLECULE, VECTOR, CELL, AND, METHODS FOR PREPARING BIOLOGICALLY ACTIVE PROTEIN CONJUGATE, AND FOR DETERMINING WHETHER A GIVEN PROTEIN CONJUGATE EXHIBITS A MODIFIED PLASMA HALF-LIFE COMPARED TO THE HALF-LIFE INTRINSIC LIFE OF BIOLOGICALLY ACTIVE NON-CONJUNGATED POLYPEPTIDE
WO2007073486A2 (en) † 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
AU2007223855B2 (en) 2006-03-06 2013-05-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
WO2008049711A1 (en) † 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BULAJ GRZEGORZ ET AL: "Efficient oxidative folding of conotoxins and the radiation of venomous cone snails.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. Supplement 2, 25 November 2003 (2003-11-25), pages 14562 - 14568, XP002515375, ISSN: 0027-8424 *
CHEN X J ET AL: "Site-directed mutations in a highly conserved region of Bacillus thuringiensis delta-endotoxin affect inhibition of short circuit current across Bombyx mori midguts.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 1 OCT 1993, vol. 90, no. 19, 1 October 1993 (1993-10-01), pages 9041 - 9045, XP002515378, ISSN: 0027-8424 *
GOMEZ-DUARTE O G ET AL: "Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 13, no. 16, 1 November 1995 (1995-11-01), pages 1596 - 1602, XP004057422, ISSN: 0264-410X *
PI C ET AL: "Analysis of expressed sequence tags from the venom ducts of Conus striatus: focusing on the expression profile of conotoxins", BIOCHIMIE, MASSON, PARIS, FR, vol. 88, no. 2, 1 February 2006 (2006-02-01), pages 131 - 140, XP025066514, ISSN: 0300-9084, [retrieved on 20060201] *

Also Published As

Publication number Publication date
AU2007223888A1 (en) 2007-09-13
EP1996220A2 (en) 2008-12-03
SI2402754T2 (en) 2023-09-29
AU2007223855B2 (en) 2013-05-16
EP1996220B2 (en) 2023-08-16
EP1996937A2 (en) 2008-12-03
SI2402754T1 (en) 2015-02-27
CA2644712A1 (en) 2007-09-13
DK2402754T4 (en) 2023-08-28
EP1996220B1 (en) 2013-05-08
WO2007103515A2 (en) 2007-09-13
AU2007223855A1 (en) 2007-09-13
EP2863222A1 (en) 2015-04-22
DK2402754T3 (en) 2015-01-12
EP1996220A4 (en) 2009-04-29
WO2007103515A3 (en) 2008-04-03
CA2644712C (en) 2016-09-13
WO2007103455A2 (en) 2007-09-13
WO2007103455A3 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
EP1996937A4 (en) Genetic packages and uses thereof
ZA200810323B (en) Fkbp-l and uses thereof
LT2064327T (en) Dbait and uses thereof
IL195658A0 (en) Anti-nkg2a antibodies and uses thereof
ZA200902823B (en) Oligoribonucleotides and uses thereof
IL196397A0 (en) Prlr-specific antibody and uses thereof
AU313875S (en) Package
IL194751A0 (en) Drugs and uses
ZA200903906B (en) Carboranylporphyrins and uses thereof
IL196861A0 (en) Antibodies against ccr5 and uses thereof
IL195525A0 (en) Replikin peptides and uses thereof
IL193469A0 (en) Novel lipases and uses thereof
GB0621160D0 (en) Compounds and uses thereof
EP2124908A4 (en) Compounds and uses thereof
EP2120563A4 (en) Compounds and uses thereof
EP2027026A4 (en) Package
PL1820741T3 (en) Package
EP2099459A4 (en) Compounds and uses thereof
GB0604187D0 (en) Peptide and uses thereof
PL2032708T3 (en) Recombinant novirhabdoviruses and uses thereof
ZA200807233B (en) Novel lipases and uses thereof
GB0603717D0 (en) Electricity-generate and store
IL192800A0 (en) Fgf2-binding peptides and uses thereof
EP2120957A4 (en) Compounds and uses thereof
GB0621665D0 (en) Blogmail and podmail

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081006

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20090305

17Q First examination report despatched

Effective date: 20090717

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AMUNIX OPERATING INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110421